EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Serum soluble E-cadherin level as a prognostic marker in patients with aggressive B-cell lymphomas

Andrey S. Komarov, Valeria G. Shestakova, Igor S. Dolgopolov, Nikolay N. Slyusar, Elena A. Chernyaeva, Maxim Yu. Rykov

Russian Journal of Oncology · 27.03.2026 · 31 (1) · 5-13

DOI: 10.17816/onco700721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Russian Journal of Oncology, online erschienen am 27.03.2026. Verfasst von Andrey S. Komarov und 5 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The criteria for therapy effectiveness and disease prognosis remain a pressing issue in oncology. The study of prognostic markers in blood serum is a promising approach for monitoring the course of B-cell lymphomas during treatment.

Aim

To analyze the relationship between the presence of the tumor process and the level of the E-cadherin marker.

Methods

The study included 53 patients (30 men, 23 women) with B-cell lymphomas (stage 1, 1 patient; stage 2A/2B, 9 patients; stage 3A/3B, 9 patients, stage 4A/4B, 34 patients). Soluble E-cadherin (sEcad) levels were measured before treatment initiation and after the third and sixth cycles of chemotherapy. The dynamics of sEcad levels were assessed both in the overall patient group and separately in subgroups of patients without relapse and with lymphoma relapse. The subgroups were comparable in age and disease stage. The control group consisted of 25 individuals (18 men, 7 women) without cancer pathology. The normal value (in patients without tumor disease) was defined as sEcad ≤1.0 ng/mL.

Results

Lymphoma relapse was observed in 22 of 53 patients (42%). Seven patients (13%) died from causes unrelated to the tumor, and one patient (2%) was lost to follow-up. The sEcad level in the overall patient group before treatment was 3.7 ± 0.4 ng/mL compared with 0.9 ± 0.1 ng/mL in the control group, p 0.0001. During therapy, a decrease in sEcad level was observed after the third and sixth chemotherapy cycles to 2.8 ± 0.3 ng/mL and 2.4±0.4 ng/mL, respectively. In the subgroups without relapse (n = 31) and with lymphoma relapse (n = 22), sEcad levels before treatment, after three cycles, and after six cycles were 3.5 ± 0.4, 2.4 ± 0.3 , and 1.5 ± 0.2 ng/mL versus 4.1 ± 0.9, 3.4 ± 0.5 , and 3.5 ± 0.7 ng/mL (p = 0.5, p = 0.1 , and p = 0.003, respectively). The sEcad level in patients without relapse significantly decreased after the sixth chemotherapy cycle compared with the time of diagnosis (p = 0.0001). Relapse-free survival (RFS) in the overall patient group was 50.3% ± 8% ; the median follow-up period was 43.9 ± 5.2 months. RFS at sEcad levels ≤1.0 ng/mL and 1.0 ng/mL after six chemotherapy cycles was 58.3 ± 16% versus 43.3 ± 11% with a median follow-up of 46.4 ± 10.3 months versus 28.2 ± 4.1 months, respectively (p = 0.045).

Conclusion

The risk of B-cell lymphoma relapse is lower when sEcad level is ≤1.0 ng/mL after six therapy cycles than at higher values of this marker. A decrease in this marker during treatment indicates a favorable response to therapy. Further studies require larger patient cohorts and standardization of sEcad measurement methods.

Zitieren

APA

Komarov, A. S., Shestakova, V. G., Dolgopolov, I. S., Slyusar, N. N., Chernyaeva, E. A., & Rykov, M. Y. (2026). Serum soluble E-cadherin level as a prognostic marker in patients with aggressive B-cell lymphomas. Russian Journal of Oncology, 31(1), 5-13. https://doi.org/10.17816/onco700721

Vancouver

Komarov AS, Shestakova VG, Dolgopolov IS, Slyusar NN, Chernyaeva EA, Rykov MY. Serum soluble E-cadherin level as a prognostic marker in patients with aggressive B-cell lymphomas. Russian Journal of Oncology. 2026;31(1):5-13. doi:10.17816/onco700721

BibTeX
@article{Komarov2026,
  author = {Komarov, Andrey S. and Shestakova, Valeria G. and Dolgopolov, Igor S. and Slyusar, Nikolay N. and Chernyaeva, Elena A. and Rykov, Maxim Yu.},
  title = {Serum soluble E-cadherin level as a prognostic marker in patients with aggressive B-cell lymphomas},
  journal = {Russian Journal of Oncology},
  year = {2026},
  volume = {31},
  number = {1},
  pages = {5--13},
  doi = {10.17816/onco700721}
}
Kostenlos starten →